Researchers have identified a promising new therapeutic strategy for autism spectrum disorder (ASD). A research team led by Director KIM Eunjoon of the IBS Center for Synaptic Brain Dysfunctions has now identified a promising new strategy for restoring NMDA receptor (NMDAR) function by targeting a glycine transporter called Slc6a20a/SLC6A20.
